A Virologist Explains: mRNA Coronavirus Vaccines And What Investors Should Know
Pfizer (NYSE: PFE) and its German partner BioNTech (NASDAQ: BNTX) reported incredible efficacy data from a phase 3 trial for their mRNA coronavirus vaccine candidate last Monday. While the 90% figure inspired much hope, investors should know this was interim data that have not yet been peer-reviewed. This week, Moderna (NASDAQ: MRNA) reported equally impressive results for its vaccine candidate that takes a similar approach.
We talked to Dr. Angela Rasmussen, a virologist and Associate Research Scientist at Columbia Center for Infection and Immunity, about what this hopeful development means for the world and for investors.
Source Fool.com
